ADC Manufacturing: The $71 Billion Boom in Bioconjugation
As the therapeutic architecture of targeted oncology grows exponentially more complex, the state of ADC Manufacturing reveals a massive industry pivot. Producing an antibody-drug conjugate is notoriously difficult; it requires…